Literature DB >> 17309101

Infrared-based protein detection arrays for quantitative proteomics.

Christian Loebke1, Holger Sueltmann1, Christian Schmidt1, Frauke Henjes1, Stefan Wiemann1, Annemarie Poustka1, Ulrike Korf1.   

Abstract

The advancement of efficient technologies to comply with the needs of systems biology and drug discovery has so far not received adequate attention. A substantial bottleneck for the time-resolved quantitative description of signaling networks is the limited throughput and the inadequate sensitivity of currently established methods. Here, we present an improved protein microarray-based approach towards the sensitive detection of proteins in the fg-range which is based on signal detection in the near-infrared range. The high sensitivity of the assay permits the specific quantification of proteins derived from as little as only 20,000 cells with an error rate of only 5%. The capacity is limited to the analysis of up to 500 different samples per microarray. Protein abundance is determined qualitatively, and quantitatively, if recombinant protein is available. This novel approach was called IPAQ (infrared-based protein arrays with quantitative readout). IPAQ offers a highly sensitive experimental approach superior to the established standard protein quantification technologies, and is suitable for quantitative proteomics. Employing the IPAQ approach, a detailed analysis of activated signaling networks in biopsy samples and of crosstalk between signaling modules as required in drug discovery strategies can easily be performed.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17309101     DOI: 10.1002/pmic.200600757

Source DB:  PubMed          Journal:  Proteomics        ISSN: 1615-9853            Impact factor:   3.984


  30 in total

Review 1.  Reverse phase protein microarrays advance to use in clinical trials.

Authors:  Claudius Mueller; Lance A Liotta; Virginia Espina
Journal:  Mol Oncol       Date:  2010-10-16       Impact factor: 6.603

2.  Combinatorial RNAi for quantitative protein network analysis.

Authors:  Ozgür Sahin; Christian Löbke; Ulrike Korf; Heribert Appelhans; Holger Sültmann; Annemarie Poustka; Stefan Wiemann; Dorit Arlt
Journal:  Proc Natl Acad Sci U S A       Date:  2007-04-09       Impact factor: 11.205

3.  [Identification and validation of clinically relevant molecular alterations in prostate cancer].

Authors:  T Schlomm; H Sültmann; J Köllermann
Journal:  Urologe A       Date:  2008-09       Impact factor: 0.639

4.  [Identification and validation of clinically relevant molecular alterations in prostate cancer].

Authors:  T Schlomm; H Sültmann; J Köllermann
Journal:  Pathologe       Date:  2009-03       Impact factor: 1.011

5.  Quantification of beta-catenin signaling components in colon cancer cell lines, tissue sections, and microdissected tumor cells using reaction monitoring mass spectrometry.

Authors:  Yi Chen; Mike Gruidl; Elizabeth Remily-Wood; Richard Z Liu; Steven Eschrich; Mark Lloyd; Aejaz Nasir; Marilyn M Bui; Emina Huang; David Shibata; Timothy Yeatman; John M Koomen
Journal:  J Proteome Res       Date:  2010-08-06       Impact factor: 4.466

6.  Unbiased RNAi screen for hepcidin regulators links hepcidin suppression to proliferative Ras/RAF and nutrient-dependent mTOR signaling.

Authors:  Katarzyna Mleczko-Sanecka; Franziska Roche; Ana Rita da Silva; Debora Call; Flavia D'Alessio; Anan Ragab; Philip E Lapinski; Ramesh Ummanni; Ulrike Korf; Christopher Oakes; Georg Damm; Lorenza A D'Alessandro; Ursula Klingmüller; Philip D King; Michael Boutros; Matthias W Hentze; Martina U Muckenthaler
Journal:  Blood       Date:  2014-01-02       Impact factor: 22.113

7.  Realizing the promise of reverse phase protein arrays for clinical, translational, and basic research: a workshop report: the RPPA (Reverse Phase Protein Array) society.

Authors:  Rehan Akbani; Karl-Friedrich Becker; Neil Carragher; Ted Goldstein; Leanne de Koning; Ulrike Korf; Lance Liotta; Gordon B Mills; Satoshi S Nishizuka; Michael Pawlak; Emanuel F Petricoin; Harvey B Pollard; Bryan Serrels; Jingchun Zhu
Journal:  Mol Cell Proteomics       Date:  2014-04-28       Impact factor: 5.911

8.  Modeling ERBB receptor-regulated G1/S transition to find novel targets for de novo trastuzumab resistance.

Authors:  Ozgür Sahin; Holger Fröhlich; Christian Löbke; Ulrike Korf; Sara Burmester; Meher Majety; Jens Mattern; Ingo Schupp; Claudine Chaouiya; Denis Thieffry; Annemarie Poustka; Stefan Wiemann; Tim Beissbarth; Dorit Arlt
Journal:  BMC Syst Biol       Date:  2009-01-01

9.  Dynamic deterministic effects propagation networks: learning signalling pathways from longitudinal protein array data.

Authors:  Christian Bender; Frauke Henjes; Holger Fröhlich; Stefan Wiemann; Ulrike Korf; Tim Beissbarth
Journal:  Bioinformatics       Date:  2010-09-15       Impact factor: 6.937

10.  Increasing the sensitivity of reverse phase protein arrays by antibody-mediated signal amplification.

Authors:  Jan C Brase; Heiko Mannsperger; Holger Fröhlich; Stephan Gade; Christian Schmidt; Stefan Wiemann; Tim Beissbarth; Thorsten Schlomm; Holger Sültmann; Ulrike Korf
Journal:  Proteome Sci       Date:  2010-06-22       Impact factor: 2.480

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.